Related Experiment Video
Updated: Feb 24, 2026

Chronic Salmonella Infection Induced Intestinal Fibrosis
Published on: September 22, 2019
NF-E2-Related Factor 2 Suppresses Intestinal Fibrosis by Inhibiting Reactive Oxygen Species-Dependent TGF-β1/SMADs
Yadi Guan1, Yue Tan1, Weiyu Liu2
1Department of Gastroenterology, Shengjing Hospital of China Medical University, 39 Huaxiang Road, Tiexi District, Shenyang, 110022, Liaoning Province, China.
Background And Aims:
This study aimed to evaluate the antifibrotic effects of NF-E2-Related Factor 2 (Nrf2) on intestinal fibrosis. Intestinal fibrosis is a common complication of Crohn's disease; however, its mechanism of intestinal fibrosis is largely unclear.
Methods:
BALB/c mice received 2,4,6-trinitrobenzene sulfonic acid weekly via intrarectal injections to induce chronic fibrotic colitis. They also diet containing received 1% (w/w) tert-butylhydroquinone (tBHQ), which is an agonist of Nrf2. Human intestinal fibroblasts (CCD-18Co cells) were pretreated with tBHQ or si-Nrf2 followed by stimulation with transforming growth factor-β1 (TGF-β1), which transformed the cells into myofibroblasts. The main fibrosis markers such as α-smooth muscle actin, collagen I, tissue inhibitor of metalloproteinase-1, and TGF-β1/SMADs signaling pathway were detected by quantitative real-time RT-PCR, immunohistochemical analysis, and Western blot analysis. Levels of cellular reactive oxygen species (ROS) were detected by dichlorodihydrofluorescein diacetate.
Results:
tBHQ suppressed the intestinal fibrosis through the TGF-β1/SMADs signaling pathway in TNBS-induced colitis and CCD-18Co cells. Moreover, Nrf2 knockdown enhanced the TGF-β1-induced differentiation of CCD-18Co cells. ROS significantly increased in TGF-β1-stimulated CCD-18Co cells. Pretreatment with H2O2, the primary component of ROS, was demonstrated to block the effect of tBHQ on reducing the expression of TGF-β1. Moreover, scavenging ROS by N-acetyl cysteine could inhibit the increasing expression of TGF-β1 promoted by Nrf2 knockdown.
Conclusions:
The results suggested that Nrf2 suppressed intestinal fibrosis by inhibiting ROS/TGF-β1/SMADs pathway in vivo and in vitro.
Insights
NF-E2-Related Factor 2 (Nrf2) suppresses intestinal fibrosis by inhibiting the ROS/TGF-β1/SMADs pathway. This study clarifies Nrf2's antifibrotic role in intestinal fibrosis, offering therapeutic insights.
Area of Science:
- Gastroenterology
- Molecular Biology
- Cell Biology
Background:
- Intestinal fibrosis is a common complication of Crohn's disease.
- The precise mechanisms underlying intestinal fibrosis remain largely unclear.
- NF-E2-Related Factor 2 (Nrf2) has potential antifibrotic effects.
Purpose of the Study:
- To evaluate the antifibrotic effects of Nrf2 in intestinal fibrosis.
- To elucidate the molecular mechanisms by which Nrf2 influences intestinal fibrosis.
- To investigate the role of reactive oxygen species (ROS) and TGF-β1/SMADs signaling in Nrf2-mediated antifibrotic activity.
Main Methods:
- Induction of chronic fibrotic colitis in BALB/c mice using TNBS.
- Administration of tert-butylhydroquinone (tBHQ), an Nrf2 agonist, to mice.
- In vitro studies using human intestinal fibroblasts (CCD-18Co cells) treated with tBHQ or Nrf2 siRNA (si-Nrf2) followed by TGF-β1 stimulation.
- Analysis of fibrosis markers (α-smooth muscle actin, collagen I, TIMP-1) and TGF-β1/SMADs pathway components via RT-PCR, immunohistochemistry, and Western blot.
- Measurement of cellular ROS levels.
Main Results:
- tBHQ treatment suppressed intestinal fibrosis in vivo and in vitro by inhibiting the TGF-β1/SMADs signaling pathway.
- Nrf2 knockdown exacerbated TGF-β1-induced myofibroblast differentiation.
- TGF-β1 stimulation increased ROS levels in intestinal fibroblasts.
- ROS, particularly H2O2, interfered with tBHQ's ability to reduce TGF-β1 expression.
- Scavenging ROS with N-acetyl cysteine inhibited TGF-β1 upregulation induced by Nrf2 knockdown.
Conclusions:
- Nrf2 exerts antifibrotic effects in intestinal fibrosis.
- Nrf2 suppresses intestinal fibrosis by inhibiting the ROS/TGF-β1/SMADs pathway.
- Targeting Nrf2 and managing ROS may represent a therapeutic strategy for intestinal fibrosis.
Related Concept Videos
TGF - β Signaling Pathway
NF-κB-dependent Signaling Pathway
NF-κB-dependent Signaling Mechanism
The...
Role of Ephrin-Eph Signalling in Intestinal Stem Cell Renewal

